Live feed07:00:00·1411dPRReleasevia QuantisnowEyePoint Pharmaceuticals and OcuMension Therapeutics Announce Approval of New Drug Application by China's NMPA for YUTIQ® for the Treatment of Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the EyeByQuantisnow·Wall Street's wire, on your screen.EYPT· EyePoint Inc.Industrials